CAI (Caris Life Sciences, Inc.) Stock Financials & Earnings

CAICaris Life Sciences, Inc.

Mkt Cap$5B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$812M

Net Income (TTM)-$538M

EPS (TTM)-$1.91

Free Cash Flow (TTM)$33M

Gross Margin66.4%

Op. Margin5.6%

Net Margin-66.2%

FCF Margin4.0%

P/S Ratio (TTM)6.5x

P/E Ratio (TTM)—

YoY Rev Growth+121.1%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q2 20	$76M	$47M	$33M
Q3 20	$79M	$49M	$36M
Q4 20	$64M	$41M	$36M
Q1 21	$81M	$39M	$49M
Q2 21	$86M	$43M	$51M
Q3 21	$101M	$54M	$66M
Q1 24	$81M	$26M	-$92M
Q2 24	$100M	$38M	$67M
Q1 25	$121M	$57M	-$58M
Q2 25	$181M	$114M	$18M
Q3 25	$217M	$148M	$33M
Q4 25	$293M	$221M	$52M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q2 20	—	$7M	$6M
Q3 20	—	$6M	$7M
Q4 20	—	$6M	—
Q1 21	—	$8M	—
Q2 21	—	$10M	—
Q3 21	—	$12M	—
Q1 24	$34M	$45M	$38M
Q2 24	$25M	$41M	$39M
Q1 25	$23M	$53M	$39M
Q2 25	$25M	$64M	$42M
Q3 25	$22M	$52M	$41M
Q4 25	$34M	$55M	$45M

Revenue by Geography

Quarter	Non-US	United States
Q2 25	$3M	$178M
Q3 25	$3M	$214M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 19	$46M	$0	$46M
Q1 20	$109M	$0	$109M
Q2 20	$48M	$0	$48M
Q3 20	$42M	$75M	$118M
Q4 20	$54M	$79M	$133M
Q1 21	$48M	$0	$48M
Q2 21	$39M	$0	$39M
Q3 21	$47M	$0	$47M
Q1 25	$31M	$2M	$33M
Q2 25	$719M	$2M	$721M
Q3 25	$753M	$2M	$755M
Q4 25	$798M	$2M	$800M

Shares Outstanding